FranceA wave of unprecedented drug patents is set to expire in the coming years, creating opportunities for generic and biosimilar pharmaceutical companies. This development is expected to lead to significant cost savings for healthcare systems. The expiration of these patents will allow other manufacturers to produce copies of the medications, increasing competition and reducing prices. This shift could reshape the pharmaceutical industry by promoting more affordable alternatives to branded drugs. The change is anticipated to become particularly impactful by 2035.
Bias read (Center): The article discusses economic changes in the pharmaceutical industry due to patent expirations, focusing on market dynamics and healthcare cost implications. It presents the situation objectively without overtly favoring any particular side or using biased language.
